Tag: Viz.Ai

Viz.ai® Announces Three New Studies Supporting Viz HCM™ Module for the Detection and Management of Suspected Hypertrophic Cardiomyopathy

April 03, 2024 08:00 AM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in cardiology care. Three studies, presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo 2024, have shown positive […]

Viz.ai and Medtronic Collaborate to Improve Post-Acute Stroke Patient Care in the United States

SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, Inc., the leader in AI-powered disease detection and intelligent care coordination, today announced a strategic collaboration with Medtronic to improve the coordination of cryptogenic stroke patient care between the neurology and cardiology teams. For stroke patients who are at risk of atrial fibrillation (“AF”) post-stroke and may need additional cardiac monitoring, stroke care teams in the U.S. will have the opportunity to use the Viz Connect™ solution,

New Viz.ai Study Demonstrates Reduced Mortality Rates in Patients with Pulmonary Embolism

SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced clinical data validating the impact of the Viz PE Solution in the management and outcomes of patients with pulmonary embolism (PE). The data was presented during the 2024 AVF (American Venous Forum) by Jacob Shapiro, M.D., vascular surgeon at TriHealth in Cincinnati, OH. The real-world study, “Shorter Time to Assessment and Anticoagulation with Decreased Mortalit

Viz.ai Announces Six Clinical Studies that Further Validate Impact of Viz™ Neuro Suite on Patient Care

SAN FRANCISCO–(BUSINESS WIRE)– #ai–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced new clinical data supporting advancements in neurovascular care. Six studies, presented at the International Stroke Conference (ISC) 2024, have shown positive outcomes with real-world impact of Viz.ai in clinical practice across various neurology pathologies including acute ischemic stroke, unruptured incidental aneurysm (UIA) and brain hemorrhage. “As a leader i

Viz.ai Announces Expansion into Outpatient Ambulatory Centers to Accelerate Clinical Trial Recruitment in Heart Failure

SAN FRANCISCO, CA – September 26, 2023 – Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the expansion into outpatient ambulatory centers to accelerate clinical trial recruitment. Amavita Heart and Vascular Health™, with facilities spanning four locations in Miami-Dade County, has taken a pioneering step by […]

Viz.ai Receives First De Novo Approval by the FDA for Hypertrophic Cardiomyopathy AI Algorithm

SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, a hypertrophic cardiomyopathy (HCM) artificial intelligence (AI) detection algorithm, creating a new regulatory category for […]

Viz.ai Appoints Hypertrophic Cardiomyopathy Medical Advisory Board to Advance Innovation

Leading experts to shape the future of Viz.ai’s HCM strategy and platform SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the creation of its Hypertrophic Cardiomyopathy (HCM) Medical Advisory Board to assist the company in the development of strategy and products to support […]

Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm

New artificial intelligence algorithm flags and triages suspected abdominal aortic aneurysms SAN FRANCISCO – March 21, 2023-  Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm […]

Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)

Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and triage patients suspected with HCM SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, […]